Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial

What this study is about

In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.

Who can join (things the study team will check)

✅ You may be able to join if…

• Documented coronary atherosclerosis, as defined by one of the following criteria:
  • Coronary artery calcium (CAC) score > 0;
  • Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery;
  • Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
• Willing and able to provide informed consent and comply with study procedures

🚫 You may not be able to join if…

• History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
• Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
• Clear contraindication to aspirin;
• History of significant bleeding within the past year;
• Severe illness with limited life expectancy (i.e., <5 years);
• Any condition that, in the investigator's judgment, would make participation unsafe for the patient.

Where this trial is running

• Montreal Heart Institute, Montreal, Quebec, Canada

Who to contact

Cyril Gagnon, MD · 514-376-3330 · cyril.gagnon@umontreal.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07524335.